Europe
Karolinska Development’s portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market.
Growth in Asia continues with ongoing investment in Headquarters site
Oxurion NV announced today it is extending its partnership with Retina Global
Significant external equity investment by a prominent pharmaceutical company in a NetScientific portfolio company
Hemogenyx Pharmaceuticals plc announces that its wholly owned subsidiary, Hemogenyx-Cell S.A. (“Hemogenyx-Cell”) has entered into a further collaboration agreement with Orgenesis, Inc (“Orgenesis”).
Medtronic plc announced today that its co-founder, Earl E. Bakken, passed away peacefully on October 21, 2018 at his home on Kiholo Bay on the Big Island of Hawaii. He was 94 years old.
What is AbbVie thinking? That’s the question of many investors, analysts and industry watchers as the Chicago-based AbbVie decided to buy up researcher partner Galapagos’ cystic fibrosis portfolio instead of walking away.
Xofluza (baloxavir marboxil) was approved for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. The new medication has a novel mechanism of action that, Roche said, inhibits polymerase acidic endonuclease, an enzyme that is essential for the flu virus to replicate.
MorphoSys AG announced today that, in a press release issued today, its licensing partner GSK reported data from their phase 2 BAROQUE clinical study of GSK3196165 (formerly MOR103) in rheumatoid arthritis (RA). The study was conducted in patients with moderate to severe RA who had an inadequate response to methotrexate.
Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancer
PRESS RELEASES